American Century Companies Inc. Has $390.43 Million Stock Holdings in Boston Scientific Corporation $BSX

American Century Companies Inc. decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 2.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 3,999,106 shares of the medical equipment provider’s stock after selling 84,219 shares during the quarter. American Century Companies Inc.’s holdings in Boston Scientific were worth $390,433,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank acquired a new stake in Boston Scientific in the second quarter valued at about $2,089,937,000. Edgewood Management LLC bought a new position in shares of Boston Scientific in the second quarter worth about $746,655,000. Parnassus Investments LLC boosted its stake in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP boosted its stake in shares of Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on BSX shares. Truist Financial dropped their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Wells Fargo & Company lowered their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group dropped their price target on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Mizuho cut their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Robert W. Baird lowered their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Boston Scientific Stock Performance

NYSE:BSX opened at $76.68 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50. The company has a fifty day moving average of $87.31 and a 200-day moving average of $95.65. The firm has a market capitalization of $113.78 billion, a P/E ratio of 39.52, a P/E/G ratio of 1.05 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the company posted $0.70 earnings per share. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.